Cargando…
The effect of neuropsychiatric medication on pediatric nonalcoholic fatty liver disease
Obese and overweight children are at risk of developing nonalcoholic fatty liver disease (NAFLD), which can lead to steatohepatitis, cirrhosis, and liver transplantation. Neuropsychiatric conditions affect an increasing proportion of children and often require neuropsychiatric medications (NPMs) tha...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468556/ https://www.ncbi.nlm.nih.gov/pubmed/35769031 http://dx.doi.org/10.1111/cts.13358 |
_version_ | 1784788438897131520 |
---|---|
author | Ryan, Jamie L. Sherman, Ashley K. Heble, Daniel E. Friesen, Craig A. Daniel, James F. Fischer, Ryan T. Slowik, Voytek |
author_facet | Ryan, Jamie L. Sherman, Ashley K. Heble, Daniel E. Friesen, Craig A. Daniel, James F. Fischer, Ryan T. Slowik, Voytek |
author_sort | Ryan, Jamie L. |
collection | PubMed |
description | Obese and overweight children are at risk of developing nonalcoholic fatty liver disease (NAFLD), which can lead to steatohepatitis, cirrhosis, and liver transplantation. Neuropsychiatric conditions affect an increasing proportion of children and often require neuropsychiatric medications (NPMs) that are associated with weight gain and/or drug‐induced liver injury. We sought to evaluate the role that the extended use of NPMs play in pediatric NAFLD. Medical chart review was conducted for 260 patients with NAFLD (NPM = 77, non‐NPM = 183) seen in the Liver Care Center at Children’s Mercy Hospital between 2000 and 2016. Outcome measures included body mass index (BMI) percentile, BMI z‐score, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, and gamma glutamyltransferase, and were collected at diagnosis, 6–18 month follow‐up, and 18–36 months. Controlling for race and metformin, there was a significant increase over time in BMI z‐score (p < 0.01) and total bilirubin (p = 0.03), with only initial decreases in ALT (p < 0.01) and AST (p < 0.01). Except for higher total bilirubin in the non‐NPM group, no main effect of group or interaction effect was found. Similar patterns remained when subjects were analyzed by NPM drug class. Further study is needed to confirm these findings and to evaluate the effects of NPM dose and duration of exposure, by drug class, on pediatric NAFLD outcomes. |
format | Online Article Text |
id | pubmed-9468556 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94685562022-09-27 The effect of neuropsychiatric medication on pediatric nonalcoholic fatty liver disease Ryan, Jamie L. Sherman, Ashley K. Heble, Daniel E. Friesen, Craig A. Daniel, James F. Fischer, Ryan T. Slowik, Voytek Clin Transl Sci Research Obese and overweight children are at risk of developing nonalcoholic fatty liver disease (NAFLD), which can lead to steatohepatitis, cirrhosis, and liver transplantation. Neuropsychiatric conditions affect an increasing proportion of children and often require neuropsychiatric medications (NPMs) that are associated with weight gain and/or drug‐induced liver injury. We sought to evaluate the role that the extended use of NPMs play in pediatric NAFLD. Medical chart review was conducted for 260 patients with NAFLD (NPM = 77, non‐NPM = 183) seen in the Liver Care Center at Children’s Mercy Hospital between 2000 and 2016. Outcome measures included body mass index (BMI) percentile, BMI z‐score, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, and gamma glutamyltransferase, and were collected at diagnosis, 6–18 month follow‐up, and 18–36 months. Controlling for race and metformin, there was a significant increase over time in BMI z‐score (p < 0.01) and total bilirubin (p = 0.03), with only initial decreases in ALT (p < 0.01) and AST (p < 0.01). Except for higher total bilirubin in the non‐NPM group, no main effect of group or interaction effect was found. Similar patterns remained when subjects were analyzed by NPM drug class. Further study is needed to confirm these findings and to evaluate the effects of NPM dose and duration of exposure, by drug class, on pediatric NAFLD outcomes. John Wiley and Sons Inc. 2022-07-09 2022-09 /pmc/articles/PMC9468556/ /pubmed/35769031 http://dx.doi.org/10.1111/cts.13358 Text en © 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Ryan, Jamie L. Sherman, Ashley K. Heble, Daniel E. Friesen, Craig A. Daniel, James F. Fischer, Ryan T. Slowik, Voytek The effect of neuropsychiatric medication on pediatric nonalcoholic fatty liver disease |
title | The effect of neuropsychiatric medication on pediatric nonalcoholic fatty liver disease |
title_full | The effect of neuropsychiatric medication on pediatric nonalcoholic fatty liver disease |
title_fullStr | The effect of neuropsychiatric medication on pediatric nonalcoholic fatty liver disease |
title_full_unstemmed | The effect of neuropsychiatric medication on pediatric nonalcoholic fatty liver disease |
title_short | The effect of neuropsychiatric medication on pediatric nonalcoholic fatty liver disease |
title_sort | effect of neuropsychiatric medication on pediatric nonalcoholic fatty liver disease |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468556/ https://www.ncbi.nlm.nih.gov/pubmed/35769031 http://dx.doi.org/10.1111/cts.13358 |
work_keys_str_mv | AT ryanjamiel theeffectofneuropsychiatricmedicationonpediatricnonalcoholicfattyliverdisease AT shermanashleyk theeffectofneuropsychiatricmedicationonpediatricnonalcoholicfattyliverdisease AT hebledaniele theeffectofneuropsychiatricmedicationonpediatricnonalcoholicfattyliverdisease AT friesencraiga theeffectofneuropsychiatricmedicationonpediatricnonalcoholicfattyliverdisease AT danieljamesf theeffectofneuropsychiatricmedicationonpediatricnonalcoholicfattyliverdisease AT fischerryant theeffectofneuropsychiatricmedicationonpediatricnonalcoholicfattyliverdisease AT slowikvoytek theeffectofneuropsychiatricmedicationonpediatricnonalcoholicfattyliverdisease AT ryanjamiel effectofneuropsychiatricmedicationonpediatricnonalcoholicfattyliverdisease AT shermanashleyk effectofneuropsychiatricmedicationonpediatricnonalcoholicfattyliverdisease AT hebledaniele effectofneuropsychiatricmedicationonpediatricnonalcoholicfattyliverdisease AT friesencraiga effectofneuropsychiatricmedicationonpediatricnonalcoholicfattyliverdisease AT danieljamesf effectofneuropsychiatricmedicationonpediatricnonalcoholicfattyliverdisease AT fischerryant effectofneuropsychiatricmedicationonpediatricnonalcoholicfattyliverdisease AT slowikvoytek effectofneuropsychiatricmedicationonpediatricnonalcoholicfattyliverdisease |